ENAn international research team led by scientists from the Max Delbrück Center in Berlin and Brigham and Women’s Hospital in Boston has created a detailed molecular map of hypertrophic cardiomyopathy, publishing their findings in Science Translational Medicine. By analyzing single-nucleus RNA from cardiac tissue across various clinical stages, the researchers identified distinct cellular mechanisms separating early and late disease phases, as well as genetic and non-genetic origins. For patients seeking specialized care at leading cardiac centers, this comprehensive dataset marks a pivotal step toward targeted, highly personalized treatment strategies that address the root causes of heart muscle disorders.
Understanding Heart Muscle Disease and Current Treatments
Heart muscle disorders, or cardiomyopathies, encompass several distinct clinical conditions that impair the heart’s ability to circulate blood efficiently. Among the most prevalent forms are hypertrophic cardiomyopathy, characterized by abnormal thickening and stiffening of the ventricular walls, and dilated cardiomyopathy, where the left ventricle expands and its muscular walls become excessively thin. Both conditions compromise cardiac output and, over time, can lead to progressive chronic heart failure.
Hypertrophic cardiomyopathy can originate from inherited genetic mutations affecting contractile proteins, or it can be acquired secondary to long-standing high blood pressure or metabolic changes. The condition affects individuals across all age groups, including young athletes and older adults, frequently developing silently without noticeable symptoms during its initial phases. As the condition advances, patients often experience exertional breathlessness, chronic fatigue, irregular heartbeats, chest discomfort, and unexplained fainting spells.
In modern German cardiac care, diagnosis relies on a combination of high-resolution cardiovascular magnetic resonance imaging, advanced echocardiography, and broad genetic screening panels. These diagnostic tools allow cardiologists to evaluate the precise geometry of the heart, map localized scar tissue formation, and stratify individual risk for adverse cardiovascular events. Current therapeutic protocols focus primarily on mitigating clinical symptoms and preventing severe complications.
Standard medical management involves pharmacological therapy using beta-blockers or calcium channel blockers to reduce muscle workload and improve diastolic filling. For patients with significant outflow obstruction, interventional procedures such as alcohol septal ablation or surgical septal myectomy are performed to relieve tissue blockage. Implantable cardioverter-defibrillators are regularly recommended for individuals identified as high-risk for dangerous ventricular arrhythmias, providing critical protection against sudden cardiac arrest.
Single-Cell RNA Insights and Artificial Intelligence
To unravel the complex cellular architecture of hypertrophic cardiomyopathy, an international team led by Dr. Eleonora Adami from Professor Norbert Hübner’s research group at the Max Delbrück Center and Dr. Yuri Kim from Brigham and Women’s Hospital analyzed cardiac tissue samples. The collaborative project brought together investigators from Harvard University, Imperial College London, University of Alberta, Helmholtz Munich, TU München, and Herz- und Diabeteszentrum NRW, focusing on single-nucleus RNA sequencing from 47 individual patients.
The researchers examined gene expression profiles from nearly one million individual heart cells, capturing tissue across the entire clinical continuum from early-stage to end-stage disease, as well as acquired non-inherited variants. They compared these data against healthy donor hearts and tissue samples from patients with dilated cardiomyopathy. The analysis revealed that during early hypertrophic cardiomyopathy, connective tissue cells known as fibroblasts produce significantly reduced levels of Collagen IV, destabilizing the structural framework that surrounds heart muscle cells.
The study further demonstrated that patients with inherited genetic forms of the disease possess fewer functional cardiomyocytes compared to healthy individuals, alongside elevated expression of genes involved in arrhythmia generation and tissue scarring. The team also identified a specific gene, designated PRR16, that directly contributes to abnormal heart cell enlargement. Utilizing this massive dataset, the researchers trained an artificial intelligence model to classify different forms and stages of cardiomyopathy based solely on gene expression profiles.
Remarkably, the machine learning model accurately distinguished between early and late disease stages, differentiated hypertrophic from dilated cardiomyopathy, and recognized whether the disease was genetic—even when analyzing gene expression exclusively from non-muscle fibroblasts. As Dr. Matthias Heinig from Helmholtz Munich emphasized, multi-omic factor analysis confirmed that diverse cell types actively shape disease signatures. Professor Norbert Hübner noted that mapping single-cell gene expression across all clinical subtypes establishes a solid foundation for developing highly specific molecular therapies.
Clinical Implications for International Patients in Germany
The creation of this molecular single-cell atlas represents a key milestone in translating basic cardiovascular science into clinical application. By establishing distinct gene expression signatures across various stages and genetic backgrounds, researchers are opening the path toward therapies that directly target aberrant cellular pathways rather than merely managing end-stage physical changes or symptomatic burdens.
While these molecular discoveries provide a framework for future drug development, their immediate clinical application involves refined risk assessment and diagnostic precision. Advanced heart centers in Germany are integrating genetic and molecular insights into their clinical diagnostic algorithms, allowing cardiologists to stratify patients more accurately and tailor current pharmacological and interventional approaches to each patient’s unique profile.
Patients undergoing diagnostic evaluation or treatment planning in Germany are encouraged to discuss detailed molecular and genetic subtyping with their attending cardiologists. Important topics to address include whether genetic testing is indicated for family members, how modern tissue imaging correlates with cellular risk markers, and what tailored clinical monitoring strategies or targeted therapeutic trials may be suitable for their specific disease subtype.
Source: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft